Quest PharmaTech (CVE:QPT) Trading Up 33.3% – Still a Buy?

Quest PharmaTech Inc. (CVE:QPT)’s share price rose 33.3% on Thursday . The stock traded as high as C$0.04 and last traded at C$0.04. Approximately 248,000 shares traded hands during trading, an increase of 429% from the average daily volume of 46,868 shares. The stock had previously closed at C$0.03.

Quest PharmaTech Stock Performance

The company has a 50-day simple moving average of C$0.03 and a two-hundred day simple moving average of C$0.04. The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40. The firm has a market capitalization of C$6.77 million, a P/E ratio of -40.00 and a beta of -0.23.

About Quest PharmaTech

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.